Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: A patent survey

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 9, 2011, Pages 1453-1471

  Dunkel, Petra ^a   Balogh, Balázs ^a   Meleddu, Rita ^b   MacCioni, Elias ^b   Gyires, Klára ^a   Mátyus, Péter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Anti inflammatory agents; Antiangiogenic agents; AOC2; AOC3; Diabetes; Semicarbazide sensitive amine oxidase; Vascular adhesion protein 1

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3 PHENYL 1H PYRAZOLO[4,3 C]PYRIDINE DERIVATIVE; ALLYLAMINE DERIVATIVE; AMINE OXIDASE (COPPER CONTAINING); AMINO ACID DERIVATIVE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; BENFOTIAMINE; BENZAMIDE DERIVATIVE; BENZYLAMINE; BTT 1023; BTT 2072; FP 1113; HETEROCYCLIC NITRO COMPOUND; HYDRAZINE DERIVATIVE; INSULIN; MOFEGILINE; MONOCLONAL ANTIBODY; OXAPROZIN; OXIME DERIVATIVE; PEPTIDE DERIVATIVE; PROTEIN INHIBITOR; PYRAZOLE DERIVATIVE; THIAMINE DERIVATIVE; THIAZOLE DERIVATIVE; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANADIUM; VASCULAR ADHESION PROTEIN 1;

ALLERGIC ENCEPHALOMYELITIS; ANTIANGIOGENIC ACTIVITY; CHEMICAL STRUCTURE; CHRONIC INFLAMMATION; DIABETES MELLITUS; DRUG LEGISLATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME SUBSTRATE; EYE DISEASE; HUMAN; IC 50; INSULIN LIKE ACTIVITY; LEUKOCYTE MIGRATION; NEOPLASM; NONHUMAN; PATENT; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION;

AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; ANTIBODIES, BLOCKING; CELL ADHESION MOLECULES; ENZYME INHIBITORS; HUMANS; HYDRAZINES; INFLAMMATION; PATENTS AS TOPIC; RNA, SMALL INTERFERING; SUBSTRATE SPECIFICITY; THIAZOLES;

EID: 80052066548     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.594040     Document Type: Review

References (167)

1. Rucker RB, O'Dell BL. Connective tissue amine oxidase I. Purification of bovine aorta amine oxidase and its comparison with plasma amine oxidase. Biochim Biophys Acta Enzymol 1971;235:32-43
2. Boomsma F. Semicarbazide-sensitive amine oxidases: widespread occurrence and many names and faces. Neurobiol (Bp) 2000;8:1-16
3. Tipton KF, O'sullivan MI, Davey GP, O'sullivan J. It can be a complicated life being an enzyme. Biochem Soc Trans 2003;31:711-15 (Pubitemid 36750763)
4. Jalkanen S, Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J 2001;20:3893-901 (Pubitemid 32751805)
5. Holt A, Alton G, Scaman CH, et al. Identification of the quinone cofactor in mammalian semicarbazide-sensitive amine oxidase. Biochemistry 1998;37:4946-57 (Pubitemid 28175977)
6. Williams NK, Klinman JP. Whence topa? Models for the biogenesis of topa quinone in copper amine oxidases. J Mol Catal B Enzym 2000;8:95-101 (Pubitemid 30035393)
7. Mure M, Mills SA, Klinman JP. Catalytic mechanism of the topa quinone containing copper amine oxidases. Biochemistry 2002;41:9269-78 (Pubitemid 34810000)
8. Brazeau BJ, Johnson BJ, Wilmot CM. Copper-containing amine oxidases. Biogenesis and catalysis; a structural perspective. Arch Biochem Biophys 2004;428:22-31 (Pubitemid 38844906)
9. Gubisne-Haberle D, Hill W, Kazachkov M, et al. Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine. J Pharmacol Exp Ther 2004;310:1125-32 (Pubitemid 39108934)
10. Matyus P, Dajka-Halasz B, Foldi A, et al. Semicarbazide-sensitive amine oxidase: current status and perspectives. Curr Med Chem 2004;11:1285-98 (Pubitemid 38585067)
11. Dunkel P, Gelain A, Barlocco D, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target. Curr Med Chem 2008;15(9):1827-39
12. Boomsma F, Bhaggoe UM, van der Houwen AMB, van den Meiracker AH. Plasma semicarbazide-sensitive amine oxidase in human (patho)physiology. Biochim Biophys Acta Proteins Proteomics 2003;1647:48-54 (Pubitemid 38234631)
13. Schwelberger HG. The origin of mammalian plasma amine oxidases. J Neural Transm 2007;114:757-62 (Pubitemid 46980481)
14. Schwelberger HG. Structural organization of mammalian copper-containing amine oxidase genes. Inflamm Res 2010;59(Suppl 2):S223-5
15. Chassande O, Renard S, Barbry P, et al. The human gene for diamine oxidase, an amiloride binding protein. Molecular cloning, sequencing, and characterization of the promoter. J Biol Chem 1994;269:14484-9
16. Imamura Y, Kubota R, Wang Y, et al. Human retina-specific amine oxidase (RAO): cDNA cloning, tissue expression, and chromosomal mapping. Genomics 1997;40:277-83 (Pubitemid 27124090)
17. Imamura Y, Noda S, Mashima Y, et al. Human retina-specific amine oxidase: genomic structure of the gene (AOC2), alternatively spliced variant, and mRNA expression in retina. Genomics 1998;51:293-8 (Pubitemid 28395037)
18. Zhang Q, Mashima Y, Noda S, et al. Characterization of AOC2 gene encoding a copper-binding amine oxidase expressed specifically in retina. Gene 2003;318:45-53 (Pubitemid 37338390)
19. Zhang X, McIntire WS. Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. Gene 1996;179:279-86 (Pubitemid 26397704)
20. Smith DJ, Salmi M, Bono P, et al. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med 1998;188:17-27 (Pubitemid 28328602)
21. Jakobsson E, Nilsson J, Ogg D, Kleywegt GJ. Structure of human semicarbazide-sensitive amine oxidase/ vascular adhesion protein-1. Acta Crystallogr D 2005;61:1550-62 (Pubitemid 43934593)
22. Airenne TT, Nymalm Y, Kidron H, et al. Crystal structure of the human vascular adhesion protein-1: Unique structural features with functional implications. Protein Sci 2005;14:1964-74 (Pubitemid 41132362)
23. Jakobsson E, Nilsson J, Kallstrom U, et al. Crystallization of a truncated soluble human semicarbazide sensitive amine oxidase. Acta Crystallogr F 2005;61:274-8 (Pubitemid 44210920)
24. Ernberg K, McGrath AP, Peat TS, et al. A new crystal form of human vascular adhesion protein 1. Acta Crystallogr F 2010;66:1572-8
25. Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 1993;178:2255-60 (Pubitemid 23344887)
26. Jaakkola K, Nikula T, Holopainen R, et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol 2000;157:463-71 (Pubitemid 30626909)
27. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 1992;257:1407-9
28. Salmi M, Jalkanen S. VAP-1: an adhesin and an enzyme. Trends Immunol 2001;22:211-16 (Pubitemid 32673661)
29. Jalkanen S, Salmi M. A novel endothelial cell molecule mediating lymphocyte binding in man. WO25582; 1993
30. Jalkanen S, Salmi M. Vascular adhesion protein-1 (VAP-1) and VAP-1 specific antibodies. US5580780; 1996
31. Biotie Therapies. Vascular adhesion protein VAP-1 having amine oxidase activity. WO53049; 1998
32. Yraola F, Albericio F, Royo M. Inhibition of VAP1: quickly gaining ground as an anti-inflammatory therapy. ChemMedChem 2007;2:173-4
33. McDonald IA, Foot J, Yin P, et al. Semicarbazide sensitive amine oxidase and vascular adhesion protein-1: one protein being validated as a therapeutic target for inflammatory diseases. Annu Rep Med Chem 2007;42:229-43
34. Salmi M, Yegutkin GG, Lehvonen R, et al. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 2001;14:265-76
35. Koskinen K, Vainio PJ, Smith DJ, et al. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1).Blood 2004;103:3388-95 (Pubitemid 38525669)
36. Andres N, Lizcano JM, Rodriguez MJ, et al. Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. J Histochem Cytochem 2001;49:209-17 (Pubitemid 32113383)
37. Ramonet D, Rodriguez M, Saura J,et al. Localization of monoamine oxidase A and B and semicarbazide-sensitive amine oxidase in human peripheral tissues. Inflammopharmacology 2003;11:111-17
38. Lyles GA. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int J Biochem Cell Biol 1996;28:259-74 (Pubitemid 26116662)
39. Massachusetts Eye & Ear Infirmary. Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (VAP-1) inhibitor. WO061830; 2009
40. Faron Ventures. Method for inhibiting angiogenesis or for treatment of cancer. WO056671; 2009
41. Noda K, She H, Nakazawa T, et al. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J 2008;22:2928-35
42. Noda K, Miyahara S, Nakazawa T, et al. Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. FASEB J 2008;22:1094-103 (Pubitemid 351519964)
43. Almulki L, Noda K, Nakao S, et al. Localization of vascular adhesion protein-1 (VAP-1) in the human eye. Exp Eye Res 2010;90:26-32
44. Forster-Horvath C, Dome B, Paku S, et al. Loss of vascular adhesion-protein-1 expression in intratumoral microvessels of human skin melanoma. Melanoma Res 2004;14:135-40 (Pubitemid 38535094)
45. Marttila-Ichihara F, Auvinen K, Elima K, et al. Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+ myeloid cells into tumors. Cancer Res 2009;69:7875-83
46. Marttila-Ichihara F, Castermans K, Auvinen K, et al. Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice. J Immunol 2010;184:3164-73
47. Benet Ferrus D, De Borja Corcostegui F, Prieto Garcia JA. Set of antiangiogenic molecules and use thereof. WO138533; 2009
48. Koskinen K, Nevalainen S, Karikoski M, et al. VAP-1-deficient mice display defects in mucosal immunity and antimicrobial responses: implications for antiadhesive applications. J Immunol 2007;179:6160-8
49. Stolen CM, Marttila-Ichihara F, Koskinen K, et al. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 2005;22:105-15 (Pubitemid 40143455)
50. Morin N, Lizcano JM, Fontana E, et al. Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes. J Pharmacol Exp Ther 2001;297:563-72 (Pubitemid 32377986)
51. Iffiu-Soltesz Z, Wanecq E, Lomba A, et al. Chronic benzylamine administration in the drinking water improves glucose tolerance, reduces body weight gain and circulating cholesterol in high-fat diet-fed mice. Pharmacol Res 2010;61:355-63
52. Carpene C, Bour S, Visentin V, et al. Amine oxidase substrates for impaired glucose tolerance correction. J Physiol Biochem 2005;61:405-20
53. Mercader J, Iffiu-Soltesz Z, Brenachot X, et al. SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders. Future Med Chem 2010;2:1735-49
54. Lizcano JM, de Arriba AF, Tipton KF, Unzeta M. Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol 1996;52:187-95 (Pubitemid 26233747)
55. Nurminen EM, Pihlavisto M, Lazar L, et al. Synthesis, in vitro activity, and three-dimensional quantitative structure-activity relationship of novel hydrazine inhibitors of human vascular adhesion protein-1. J Med Chem 2010;53:6301-15
56. Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases. WO02090; 2002
57. Biotie Therapies Corp. Crystalline VAP-1 and uses thereof. WO104191; 2004
58. Biotie Therapies Corp. Hydrazino alcohol derivatives useful as inhibitors of copper-containing amine oxidases. WO080319; 2005
59. Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases. WO006003; 2003
60. Marttila-Ichihara F, Smith DJ, Stolen C, et al. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum 2006;54:2852-62 (Pubitemid 44497764)
61. Kiss J, Jalkanen S, Fulop F, et al. Ischemia-reperfusion injury is attenuated in VAP-1-deficient mice and by VAP-1 inhibitors. Eur J Immunol 2008;38:3041-9
62. Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases. WO02541; 2002
63. Fulop F, Lazar L, Szakonyi Z, et al. Discovery of new anti-inflammatory agents. Pure Appl Chem 2004;76:965-72
64. R-Tech Ueno Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor. WO145360; 2009
65. La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases. WO014530; 2005
66. La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases. WO094201; 2006
67. Airas L, Mikkola J, Vainio JM, et al. Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. J Neuroimmunol 2006;177:132-5 (Pubitemid 44131575)
68. O'Rourke AM, Wang EY, Salter-Cid L, et al. Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. J Neural Transm 2007;114:845-9 (Pubitemid 46980496)
69. Castillo V, Lizcano JM, Visa J, Unzeta M. Semicarbazide-sensitive amine oxidase (SSAO) from human and bovine cerebrovascular tissues: biochemical and immunohistological characterization. Neurochem Int 1998;33:415-23 (Pubitemid 28559220)
70. Xu H, Salter-Cid L, Linnik MD, et al. Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia. J Pharmacol Exp Ther 2006;317:19-29
71. Jaakkola K, Jalkanen S, Kaunismaki K, et al. Vascular adhesion protein-1, intercellular adhesion molecule-1 and P-selectin mediate leukocyte binding to ischemic heart in humans. J Am Coll Cardiol 2000;36:122-9 (Pubitemid 30466122)
72. Wang EY, Gao H, Salter-Cid L, et al. Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity. J Med Chem 2006;49:2166-73
73. Salter-Cid LM, Wang E, O'Rourke AM, et al. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. J Pharmacol Exp Ther 2005;315:553-62 (Pubitemid 41500719)
74. Sucampo Ag. Fujisawa Pharmaceutical Co. Ltd. Method for treating vascular hyperpermeable disease. WO087138; 2004
75. Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and their use as VAP-1 inhibitors. WO067521; 2004
76. Noda K, Nakao S, Zandi S, et al. Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes. Exp Eye Res 2009;89:774-81
77. Astellas Pharma, Inc. Thiazole derivatives having VAP-1 inhibitory activity. WO011631; 2006
78. Astellas Pharma, Inc. Thiazole derivatives having VAP-1 inhibitory activity. WO028269; 2006
79. R-Tech Ueno Ltd. Aqueous composition comprising thiazole derivative. WO089755; 2005
80. R-Tech Ueno Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor. WO096609; 2009
81. R-Tech Ueno Ltd. Pharmaceutical composition for treatment of cataract. US0210697; 2010
82. R-Tech Ueno Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor. WO066145; 2008
83. R-Tech Ueno Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia. US0190834; 2010
84. Biovitrum AB. New use of 4,5,6,7-tetrahydroimidazo-[4,5-c]pyridine derivatives. WO38153; 2002
85. Biovitrum AB. New compounds I. WO031789; 2010
86. Proximagen Ltd. Imidazopyridine compounds. WO064020; 2010
87. Biovitrum AB. New compounds II. WO031791; 2010
88. Merrel Dow Pharmaceuticals, Inc. (E)-2-(p-fluorophenethyl)-3- fluoroallylamine. EP0295604; 1988
89. Foley P, Gerlach M, Youdim MBH, Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord 2000;6:25-47
90. La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases. WO120528; 2007
91. La Jolla Pharmaceutical Co. Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases. WO082343; 2005
92. Zhang Y, Ran C, Zhou G, Sayre LM. Highly potent 3-pyrroline mechanismbased inhibitors of bovine plasma amine oxidase and mass spectrometric confirmation of cofactor derivatization. Bioorg Med Chem 2007;15:1868-77 (Pubitemid 46394039)
93. Lee Y, Ling K, Lu X, et al. 3-Pyrrolines are mechanism-based inactivators of the quinone-dependent amine oxidases but only substrates of the flavin-dependent amine oxidases. J Am Chem Soc 2002;124:12135-43 (Pubitemid 35154880)
94. Yu PH, Lu L, Fan H, et al. Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in lipopolysaccharide-induced pulmonary inflammation. Am J Pathol 2006;168:718-26 (Pubitemid 43327724)
95. O'Rourke AM, Wang EY, Miller A, et al. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl) allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J Pharmacol Exp Ther 2008;324:867-75 (Pubitemid 351185861)
96. Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor. WO066152; 2009
97. La Jolla Pharmaceutical Co. Combined inhibitors of cyclooxygenase and semicarbazide-sensitive amine oxidase (SSAO) (vascular adhesion protein, VAP-1).WO055002; 2009
98. Genmedica Therapeutics. Compounds for inhibiting copper-containing amineoxidases and uses thereof. WO013209; 2006
99. Genmedica Therapeutics. Compounds for inhibiting copper-containing amine oxidases and uses thereof. US0066646; 2007
100. Semmelweis Egyetem. Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/ vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases. WO029379; 2010
101. O'sullivan J, O'sullivan M, Tipton KF, et al. The inhibition of semicarbazide-sensitive amine oxidase by aminohexoses. Biochim Biophys Acta Proteins Proteomics 2003;1647:367-71 (Pubitemid 38234681)
102. Faron Pharmaceuticals. Aminoglycoside antibiotics for use as VAP-1/SSAO inhibitors. WO063261; 2005
103. Faron Pharmaceuticals. Compositions useful especially for treatment or prevention of metabolic syndrome. US0206313; 2008
104. Faron Pharmaceuticals. Compositions useful especially for treatment or prevention of metabolic syndrome. WO025870; 2008
105. Faron Pharmaceuticals. Compositions for targeting amine oxidases in vivo. WO128951; 2006
106. Yegutkin GG, Salminen T, Koskinen K, et al. A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress. Eur J Immunol 2004;34:2276-85 (Pubitemid 39256109)
107. Faron Ventures. Novel peptides. WO077993; 2008
108. Kivi E, Elima K, Aalto K, et al. Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. Blood 2009;114:5385-92
109. Ujula T, Salomaki S, Virsu P, et al. Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis. Nucl Med Biol 2009;36:631-41
110. Lankinen P, Makinen TJ, Poyhonen TA, et al. 68Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones. Eur J Nucl Med Mol Imaging 2008;35:352-64
111. Silvola J, Autio A, Luoto P, et al. Preliminary evaluation of novel 68Ga-DOTAVAP-PEG-P2 peptide targeting vascular adhesion protein-1. Clin Physiol Funct Imaging 2010;30:75-8
112. Faron Pharmaceuticals. Compounds for treating or preventing amine oxidase related diseases or disorders. WO134203; 2006
113. Merinen M, Irjala H, Salmi M, et al. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol 2005;166:793-800 (Pubitemid 40315636)
114. Biotie Therapies Corp. Novel humanized anti-VAP-1 monoclonal antibody. WO093319; 2003
115. Kirton CM, Laukkanen M, Nieminen A, et al. Function-blocking antibodies to human vascular adhesion protein-1: A potential anti-inflammatory therapy. Eur J Immunol 2005;35:3119-30 (Pubitemid 41672517)
116. Biotie Therapies Corp. Novel fully human anti-VAP-1 monoclonal antibodies. WO129124; 2008
117. Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, et al. Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis. Basic Clin Pharmacol Toxicol 2005;96:429-35 (Pubitemid 40835697)
118. Bono P, Jalkanen S, Salmi M. Mouse vascular adhesion protein 1 is a sialoglycoprotein with enzymatic activity and is induced in diabetic insulitis. Am J Pathol 1999;155:1613-24
119. Salmi M, Stolen C, Jousilahti P, et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 2002;161:2255-62 (Pubitemid 35434869)
120. Li H, Lin M, Wei J, et al. Change of serum vascular adhesion protein-1 after glucose loading correlates to carotid intima-medial thickness in non-diabetic subjects. Clin Chim Acta 2009;403:97-101
121. Li H, Wei J, Lin M, et al. Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. Clin Chim Acta 2009;404:149-53
122. Visentin V, Bour S, Boucher J, et al. Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide. Eur J Pharmacol 2005;522:139-46 (Pubitemid 41456660)
123. Yu PH, Wang M, Fan H, et al. Involvement of SSAO-mediated deamination in adipose glucose transport and weight gain in obese diabetic KKAy mice. Am J Physiol Endocrinol Metab 2004;286:E634-41
124. Roessner V, Weber A, Becker A, et al. Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: a link to impaired glucose metabolism? Eur J Clin Pharmacol 2007;63:425-9 (Pubitemid 46569919)
125. Stolen CM, Madanat R, Marti L, et al. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 2004;18:702-4
126. Marti L, Abella A, de la Cruz X, et al. Exploring the binding mode of semicarbazide-sensitive amine oxidase/ VAP-1: identification of novel substrates with insulin-like activity. J Med Chem 2004;47:4865-74 (Pubitemid 39238261)
127. Yraola F, Garcia-Vicente S, Fernandez-Recio J, et al. New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: analysis by SARs and computational docking. J Med Chem 2006;49:6197-208 (Pubitemid 44595197)
128. Bonaiuto E, Lunelli M, Scarpa M, et al. A structure-activity study to identify novel and efficient substrates of the human semicarbazide-sensitive amine oxidase/VAP1 enzyme. Biochimie 2010;92:858-68
129. Universidad de Barcelona. Combination of amines and vanadium(IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus. WO38152; 2002
130. Genmedica Therapeutics. Compositions of SSAO substrates and metal compounds of the VIA and VIB groups of the periodic table. WO061140; 2006
131. Genmedica Therapeutics. Meta-xylylenediamine vanadate salts. WO131996; 2007
132. Yraola F, Garcia-Vicente S, Marti L, et al. Understanding the mechanism of action of the novel SSAO substrate (C7NH10)6(V10O28) 2H2O, a prodrug of peroxovanadate insulin mimetics. Chem Biol Drug Des 2007;69:423-8
133. Zorzano A, Palacin M, Marti L, Garcia-Vicente S. Arylalkylamine vanadium salts as new anti-diabetic compounds. J Inorg Biochem 2009;103:559-66
134. VAP-1 antibody product profile. Biotie 2011.Available from: [Last accessed April 2011]
135. Lewinsohn R. Human serum amine oxidase. Enzyme activity in severely burnt patients and in patients with cancer. Clin Chim Acta 1977;81:247-56 (Pubitemid 8221823)
136. Toiyama Y, Miki C, Inoue Y, et al. Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis. J Surg Oncol 2009;99:368-72
137. Garpenstrand H, Bergqvist M, Brattstrom D, et al. Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients. Med Oncol 2004;21:241-50 (Pubitemid 39469764)
138. Ekblom J, Gronvall J, Lennernast B, et al. Elevated activity of semicarbazide-sensitive amine oxidase in blood from patients with skeletal metastases of prostate cancer. Clin Sci 1999;97:111-15 (Pubitemid 29353903)
139. Irjala H, Salmi M, Alanen K, et al. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J Immunol 2001;166:6937-43 (Pubitemid 32467241)
140. Maula S, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003;63:1920-6 (Pubitemid 36460859)
141. Enzsoly A, Dunkel P, Recsan Z, et al. Preliminary studies of the effects of vascular adhesion protein-1 inhibitors on experimental corneal neovascularization. J Neural Transm 2011;DOI:10.1007/s00702-011-0595-8
142. Boomsma F, van Veldhuisen DJ, de Kam PJ, et al. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 1997;33:387-91 (Pubitemid 27072644)
143. Boomsma F, De Kam PJ, Tjeerdsma G, et al. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur Heart J 2000;21:1859-63
144. Olive M, Unzeta M, Moreno D, Ferrer I. Overexpression of semicarbazide-sensitive amine oxidase in human myopathies. Muscle Nerve 2004;29:261-6 (Pubitemid 38166849)
145. Boomsma F, van den Meiracker AH, Winkel S, et al. Circulating semicarbazide-sensitive amine oxidase is raised both in Type I (insulindependent), in Type II (non-insulindependent) diabetes mellitus and even in childhood Type I diabetes at first clinical diagnosis. Diabetologia 1999;42:233-7 (Pubitemid 29064246)
146. Boomsma F, Pedersen-Bjergaard U, Agerholm-Larsen B, et al. Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus. Diabetologia 2005;48:1002-7 (Pubitemid 40767995)
147. Meszaros Z, Szombathy T, Raimondi L, et al. Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 1999;48:113-17 (Pubitemid 29035570)
148. Karadi I, Meszaros Z, Csanyi A, et al. Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin Chim Acta 2002;323:139-46 (Pubitemid 34804803)
149. Nunes SF, Figueiredo IV, Soares PJ, et al. Semicarbazide-sensitive amine oxidase activity and total nitrite and nitrate concentrations in serum: novel biochemical markers for type 2 diabetes? Acta Diabetol 2009;46:135-40
150. Nunes SF, Figueiredo IV, Pereira JS. Changes in the activities of semicarbazide-sensitive amine oxidase in inferior mesenteric artery segments and in serum of patients with type 2 diabetes. Acta Diabetol 2010;47:179-82
151. Gronvall-Nordquist JLE, Backlund LB, Garpenstrand H, et al. Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus. J Diabetes Complications 2001;15:250-6 (Pubitemid 32750612)
152. Garpenstrand H, Ekblom J, Backlund LB, et al. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy. Diabetic Med 1999;16:514-21
153. Weiss HG, Klocker J, Labeck B, et al. Plasma amine oxidase: a postulated cardiovascular risk factor in nondiabetic obese patients. Metabolism 2003;52:688-92 (Pubitemid 36896300)
154. Dullaart RPF, Riemens SC, Boomsma F. Plasma semicarbazide-sensitive amine oxidase is moderately decreased by pronounced exogenous hyperinsulinemia but is not associated with insulin sensitivity and body fat. Scand J Clin Lab Invest 2006;66:559-66 (Pubitemid 44764389)
155. Visentin V, Prevot D, De Saint Front VD, et al. Alteration of amine oxidase activity in the adipose tissue of obese subjects. Obes Res 2004;12:547-55 (Pubitemid 41132535)
156. Madej A, Reich A, Orda A, Szepietowski JC. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol 2007;21:72-8 (Pubitemid 44942327)
157. Madej A, Reich A, Orda A, Szepietowski JC. Expression of vascular adhesion protein-1 in atopic eczema. Int Arch Allergy Immunol 2006;139:114-21 (Pubitemid 43177322)
158. Ferrera I, Lizcano JM, Hernandez M, Unzeta M. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett 2002;321:21-4 (Pubitemid 34185489)
159. Jiang ZJ, Richardson JS, Yu PH. The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathol Appl Neurobiol 2008;34:194-204 (Pubitemid 351327961)
160. Unzeta M, Sole M, Boada M, Hernandez M. Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage inAlzheimer's disease. J Neural Transm 2007;114:857-62 (Pubitemid 46980498)
161. del Mar Hernandez M, Esteban M, Szabo P, et al. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett 2005;384:183-7 (Pubitemid 40826641)
162. Nemcsik J, Szoko e, Soltesz Z, et al. Alteration of serum semicarbazide-sensitive amine oxidase activity in chronic renal failure. J Neural Transm 2007;114:841-3 (Pubitemid 46980495)
163. Lin M, Li H, Wei J, et al. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem 2008;41:1362-7
164. Kurkijarvi R, Jalkanen S, Isoniemi H, Salmi M. Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. Eur J Immunol 2001;31:2876-84 (Pubitemid 32994538)
165. Kurkijarvi R, Adams DH, Leino R, et al. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 1998;161:1549-57 (Pubitemid 28380589)
166. Kurkijarvi R, Yegutkin GG, Gunson BK, et al. Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology 2000;119:1096-103
167. Airas L, Lindsberg PJ, Karjalainen-Lindsberg M, et al. Vascular adhesion protein-1 in human ischaemic stroke. Neuropathol Appl Neurobiol 2008;34:394-402